A Novartis drug that delivers a lethal dose of radiation directly to prostate cancer cells delayed tumor growth and extended survival in men with advanced disease, according to results of a late-stage clinical trial.
Treatment with what Novartis calls radioligand therapy — thankfully, because its scientific name is 177Lu-PSMA-617 — reduced the risk of death by 38% compared with standard drugs. The risk of tumor progression was cut by 60%. Both outcomes achieved the main goals of the Phase 3 study with statistical significance.
About the Author Reprints
